Literature DB >> 6611342

Permissive effect of cytochalasin B on DNA synthesis in concanavalin-A-treated lymphocytes.

K G Sundqvist, L Wanger, W Ensgstöm.   

Abstract

Unfractionated or T-cell-enriched human lymphocytes can be stimulated to undergo DNA synthesis and mitosis by the addition of polyclonal cell activators such as the plant lectins phytohaemagglutinin and concanavalin A (ConA). Under conventional culture conditions stimulated cells cease proliferating only a few days after the first cells have initiated DNA synthesis. Cytochalasin B (CB), which is non-mitogenic per se, causes a prolongation of the period during which ConA stimulates DNA synthesis from normally 3-5 days to more than 3 weeks. The CB-induced prolongation of cell proliferation is clearly stage-specific in the sense that the CB effects are exerted after an initial period of 24 h and do not come into effect until 48 h after onset of ConA stimulation. In contrast, CB exerts a slight suppressive action on DNA synthesis between 24 h (when activated cells initiate DNA synthesis) and 48 h after onset of stimulation. These two separate effects of CB, i.e. augmentation of lymphocyte stimulation 48 h after stimulation, and suppression of stimulation before this point of time, are relatively independent of the concentration of CB.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6611342     DOI: 10.1242/jcs.66.1.155

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  2 in total

1.  Phagocytosis and protein processing are required for presentation of Cryptococcus neoformans mitogen to T lymphocytes.

Authors:  R M Syme; J C Spurrell; L L Ma; F H Green; C H Mody
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

2.  A cytokine-controlled mechanism for integrated regulation of T-lymphocyte motility, adhesion and activation.

Authors:  Sten-Erik Bergström; Eva Bergdahl; Karl-Gösta Sundqvist
Journal:  Immunology       Date:  2013-12       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.